Population Pharmacokinetics of Osimertinib in Patients With Non‐Small Cell Lung Cancer
Martin Johnson, Yu‐Wei Lin, Henning Schmidt, Mikael Sunnåker et autres
7 citationsPharmacology Research & Perspectives
Martin Johnson
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
51Publications signalées
1097Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Schizophrenia research and treatmentLung Cancer Treatments and MutationsNeurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionPI3K/AKT/mTOR signaling in cancer
Publications récentes
Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer
Martin Johnson, Yu‐Wei Lin, Henning Schmidt, Mikael Sunnåker et autres
9 citationsBritish Journal of Clinical Pharmacology
Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors
Martin Johnson, Daniel Kaschek, Dana Ghiorghiu, Shankar Lanke et autres
4 citationsThe Journal of Clinical Pharmacology
In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
Linda Wanika, Neil D. Evans, Martin Johnson, Helen Tomkinson et autres
4 citationsClinical and Translational Science
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First‐Line Mutant Epidermal Growth Factor Receptor Non‐Small Cell Lung Cancer
Martin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, Philip Overend et autres
9 citationsClinical Pharmacology & Therapeutics
MA18.11 A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients
Ming Hong, Bing Gao, Youwei Cheng, B.-Y. Shim et autres
1 citationJournal of Thoracic Oncology
The potential and pitfalls of artificial intelligence in clinical pharmacology
Martin Johnson, Mishal Patel, Alex Phipps, Mihaela van der Schaar et autres
36 citationsCPT Pharmacometrics & Systems Pharmacology
Machine Learning Models for Human In Vivo Pharmacokinetic Parameters with In-House Validation
Filip Miljković, Anton Martinsson, Olga Obrezanova, Beth Williamson et autres
95 citationsMolecular Pharmaceutics
Abstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
Karthick Vishwanathan, James Dunyak, Philip Overend, Ryan J. Hartmaier et autres
1 citationCancer Research
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
Karthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, Nicolas Penel et autres
15 citationsPharmacology Research & Perspectives
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han et autres
173 citationsJournal of Thoracic Oncology
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Jhanelle E. Gray, Nir Peled, Aleksandra Markovets, Naoyuki Nogami et autres
9 citationsAnnals of Oncology
BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.